(RECORDING) ANCILLARY SYMPOSIUM - SEVERE HYPOGLYCEMIA: THE FREQUENTLY FORGOTTEN THREAT

This program featured informative sessions directed by key opinion leaders who will discuss different aspects of diabetes technology from the scientific basis to the clinical integration of diabetes technology and time in range in their day to day practice. A case workshop will follow the educational series where challenging, real clinical cases will be provided to the attendees and attendees will answer the case questions through the Audience Response System (ARS). Following each case, the expert faculty presenters will discuss their approach to the cases. This symposium is certified for 1.5 AMA PRA Category 1 Credits™ and 1.5 ABIM MOC points.

Target Audience

This activity is intended for endocrinologists and endocrine fellows, primary care physicians, physician’s assistants, nurse practitioners and other healthcare professionals. 

Learning Objectives

Upon completion of this educational activity, learners will be able to: 

  • Better understand risks related to hypoglycemia
  • Decrease the frequency and severity of hypoglycemia as an ADE among patients with T2D on insulin and/ or Sus who are identified as high risk
  • Discuss the role of currently available pipeline methods to lower hypoglycemia risk

Additional Information

Partner: 
Endocrine Society
Course summary
Available credit: 
  • 1.50 MOC
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 Participation
Course opens: 
07/13/2020
Course expires: 
07/13/2021
Rating: 
0
Michael McDermott, MD- Program Chair 

Professor

University of Colorado Hospital

Aurora, CO 

Elizabeth Seaquist, MD 

Professor 

University of Minnesota

Minneapolis, MN

Cecilia Low Wang, MD 

Professor 

University of Colorado  

Denver, CO

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. 

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable. 

The following faculty reported no relevant financial relationships during the content development process for this activity:  

  • Michael McDermott, MD (Chair)Cecilia Low Wang, MD 

The following faculty reported  relevant financial relationships during the content development process for this activity:  

  • Elizabeth Seaquist, MD  Advisory Board Member, Mannkind Corporation, Zucara; Research Investigator, Eli Lilly & Company

The following Special Programs Committee member who planned and reviewed content for this activity reported no relevant financial relationships:  

  •  Beret Ann Casey, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

USE OF PROFESSIONAL JUDGMENT: The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES: When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT This educational activity is supported by an independent medical educational grant from Lilly USA.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™ and 1.5 ABIM MOC Points. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC) Statement:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to: 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at education.endocrine.org/contact.

Available Credit

  • 1.50 MOC
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 Participation
Please login or register to take this course.

This course is offered through Endocrine Society. To take this course you will be redirected to Endocrine Society's website. You must have an account with Endocrine Society in order to complete this activity. 

Mocingbird continues to work with our CME partner network to provide courses directly to you. We appreciate your patience as we work toward that goal!